Kirk Druey, M.D.

The LVIS conducts broad and in-depth translational research that focuses on fundamental processes underlying allergic inflammation. Our research program includes studies aimed at mechanistic dissection of fungal associated-asthma and exploration of the pathogenesis of the rare vascular disorder resembling systemic anaphylaxis, a condition known as systemic capillary leak syndrome (SCLS, Clarkson disease). SCLS is a life-threatening disorder of unknown etiology in which patients experience spontaneous and recurrent episodes of hypovolemic shock and edema in the absence of allergic triggers. In the area of fungal asthma, we have identified a fungal protease allergen (Alp1) that is deposited in the airways of patients with severe asthma, and we have elucidated detailed mechanisms by which Alp1 promotes airway smooth muscle contraction and bronchoconstriction. Finally, ongoing studies in the LVIS include G protein-coupled receptor (GPCR)-dependent mechanisms of allergic inflammation, more specifically on the role of Regulators of G protein Signaling (RGS) proteins in lung and inflammatory cells.